-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, according to Reuters, citing two people familiar with the matter, Mundipharma has included Boyu Capital and Sinopharm on the list of bidders for its business in China
.
In addition, Chinese mergers and acquisitions companies CITIC Capital (CITIC Capital) and CITIC Industry Fund (CPE) are also on the bidding candidates list
.
It was previously reported that the price of this sector may exceed 1 billion U.
S.
One of the people familiar with the matter said that Mundi Pharmaceuticals has screened out about half of about 20 initial potential buyers to enter the next round, including private equity companies and strategic investors
.
Reuters reported that the offer for the second round of bidding is non-binding and will be conducted in July
.
Bidders also include private equity firms globally and in various regions
It is reported that at the same time that Mengdi sold its Chinese business, its owner, the Sackler family, proposed a $4.
3 billion settlement agreement to resolve the opioid lawsuit faced by Purdue Pharmaceuticals in the United States
Both Mundi Pharmaceuticals and Purdue Pharmaceuticals are owned by the Sackler family
.
Purdue Pharmaceuticals is an American opioid manufacturer.
Mundi Pharmaceuticals is responsible for the sales of Purdue Pharmaceuticals products overseas
According to data, Purdue Pharmaceuticals has been investigated by US officials for a painkiller called OxyContin
.
In the end, Purdue Pharmaceuticals pleaded guilty to three felony crimes (including defrauding the United States and violating the federal anti-kickback law) from 2009 to 2017, pleaded guilty to high compensation of approximately 54.
5 billion yuan, and declared bankruptcy
At present, the case has become a landmark case in the United States trying to control the abuse of opioids.
In addition to Purdue Pharmaceuticals, many well-known pharmaceutical companies, including Johnson & Johnson, Allergan, and Teva Pharmaceuticals, are also involved
A few days ago, according to Reuters, citing two people familiar with the matter, Mundipharma has included Boyu Capital and Sinopharm on the list of bidders for its business in China
.
In addition, Chinese mergers and acquisitions companies CITIC Capital (CITIC Capital) and CITIC Industry Fund (CPE) are also on the bidding candidates list
.
It was previously reported that the price of this sector may exceed 1 billion U.
S.
dollars (about 6.
3 billion yuan)
One of the people familiar with the matter said that Mundi Pharmaceuticals has screened out about half of about 20 initial potential buyers to enter the next round, including private equity companies and strategic investors
.
Reuters reported that the offer for the second round of bidding is non-binding and will be conducted in July
.
Bidders also include private equity firms globally and in various regions
It is reported that at the same time that Mengdi sold its Chinese business, its owner, the Sackler family, proposed a $4.
3 billion settlement agreement to resolve the opioid lawsuit faced by Purdue Pharmaceuticals in the United States
.
Both Mundi Pharmaceuticals and Purdue Pharmaceuticals are owned by the Sackler family
.
Purdue Pharmaceuticals is an American opioid manufacturer.
Mundi Pharmaceuticals is responsible for the sales of Purdue Pharmaceuticals products overseas
.
The two are actually the same company, and Purdue Pharmaceutical's previous quagmire in the United States in the quagmire of high-priced compensation was the fuse for Mundi Pharmaceuticals to sell its Chinese business
.
According to data, Purdue Pharmaceuticals has been investigated by US officials for a painkiller called OxyContin
.
In the end, Purdue Pharmaceuticals pleaded guilty to three felony crimes (including defrauding the United States and violating the federal anti-kickback law) from 2009 to 2017, pleaded guilty to high compensation of approximately 54.
5 billion yuan, and declared bankruptcy
.
At present, the case has become a landmark case in the United States trying to control the abuse of opioids.
In addition to Purdue Pharmaceuticals, many well-known pharmaceutical companies, including Johnson & Johnson, Allergan, and Teva Pharmaceuticals, are also involved
.
( Sina Pharmaceutical News )
